Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25844692 | 0.98 | KDM4E (0.34) | TP53MAPTKDM4EMEN1KMT2A | |
| SCHEMBL25529761 | 0.96 | TP53 (0.32) | TP53MAPTKDM4EMEN1KMT2A | |
| SCHEMBL25844695 | 0.96 | KDM4E (0.35) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25844009 | 0.95 | TP53 (0.34) | TP53MAPTKDM4EMEN1KMT2A | |
| SCHEMBL25529849 | 0.94 | KDM4E (0.35) | TP53MAPTKDM4EMEN1KMT2A | |
| SCHEMBL30476316 | 0.94 | KDM4E (0.32) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL26646556 | 0.93 | TP53 (0.32) | TP53MAPT | |
| SCHEMBL25836099 | 0.93 | KDM4E (0.31) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL25844011 | 0.93 | TP53 (0.32) | TP53MAPTKDM4EMEN1KMT2A | |
| SCHEMBL1009670 | 0.93 | KDM4E (0.36) | TP53MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340318-A1 | PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES | HOYA LENS THAILAND LTD. (TH) | 2023-10-26 | — | — | US | disclosed |
| US-20230227717-A1 | PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND SPECTACLES | HOYA LENS THAILAND LTD. (TH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340318-A1 | PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES | NR2E3, CRY1, RPS10 | TP53 4259/4885MAPT 3015/4885KDM4E 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.